Long Bridge Medical Secures U.S. Food and Drug Administration Clearance to Launch Pivotal U.S. Study of LensOne Prosthetic Capsular Bag
Long Bridge Medical, Inc. has reached an important regulatory milestone with the clearance from the U.S. Food and Drug Administration (FDA) to initiate its Investigational Device Exemption (IDE) study for LensOne™, an innovative prosthetic capsular bag designed to improve outcomes in complex ophthalmic cases. This development enables the company to move forward with its pivotal clinical study, known as the GOLDEN GATE trial, which will evaluate the safety and effectiveness of the LensOne device in patients who require secondary intraocular lens (IOL) implantation but lack adequate capsular support.
The LensOne system has been developed to address a significant clinical challenge faced by ophthalmic surgeons. In many patients, the natural lens capsule—which typically provides structural support for intraocular lens placement—is either absent or compromised due to prior surgery, trauma, or degenerative conditions. These cases often leave surgeons with limited and suboptimal treatment options, particularly for patients who are not suitable candidates for anterior chamber intraocular lenses (ACIOLs). By offering a prosthetic capsular bag, LensOne aims to restore a more natural anatomical environment for IOL fixation, potentially improving both surgical consistency and visual outcomes.
The newly approved GOLDEN GATE trial is designed as a prospective, multicenter study, reflecting a rigorous approach to clinical evaluation. The trial will enroll patients experiencing IOL dislocation who are also considered poor candidates for ACIOL procedures. Through this study, Long Bridge Medical intends to generate robust clinical evidence that could support regulatory approval and ultimately position LensOne as a new standard of care in this underserved patient population.
The FDA’s clearance of the IDE application builds upon earlier recognition of LensOne’s potential. The device had previously received Breakthrough Device Designation from the agency, a status reserved for technologies that demonstrate the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation not only underscores the clinical importance of the problem LensOne seeks to solve but also reflects confidence in the device’s innovative approach to addressing it.
The need for improved solutions in secondary IOL fixation is substantial. Tens of thousands of patients across the United States require secondary lens implantation each year due to conditions such as post-surgical aphakia, ocular trauma, or spontaneous IOL dislocation. These scenarios are often complex and technically demanding, requiring advanced surgical expertise and careful intraoperative decision-making. Current techniques, including scleral suture fixation and the Yamane method, Long Bridge Medical are widely used but present notable limitations. They are technically challenging, involve steep learning curves, and can be associated with complications such as suture degradation, lens tilt, or long-term instability.
Moreover, these existing approaches are largely off-label and lack a standardized, reproducible framework, which can lead to variability in patient outcomes. This variability highlights the pressing need for a more consistent and reliable solution—one that can simplify surgical procedures while maintaining or improving safety and efficacy. LensOne has been specifically engineered to address these challenges by providing a structured platform for IOL placement, potentially reducing surgical complexity and enhancing reproducibility.
Dr. Frank Brodie, Co-Founder of Long Bridge Medical, emphasized the significance of this milestone, noting that the IDE clearance represents a critical step forward not only for the company but also for patients and surgeons alike. He highlighted the difficulties associated with current treatment options and the unmet need for better alternatives. According to Dr. Brodie, LensOne was designed with the goal of transforming how these challenging cases are managed, offering a tool that could improve both surgical experience and patient outcomes.
The company’s confidence in LensOne is supported by encouraging early clinical data. Long Bridge Medical previously reported results from a first-in-human study involving 15 patients, with follow-up extending to 12 months. The findings demonstrated a favorable safety and performance profile, providing preliminary evidence that the device could deliver on its intended benefits. These results served as a foundation for advancing to a larger, U.S.-based pivotal study.
Notably, the initial clinical data were presented by Dr. J. Michael Jumper, President of the American Society of Retina Specialists (ASRS), at the organization’s 2025 annual meeting. This Long Bridge Medical presentation brought additional visibility to the technology within the ophthalmology community and reinforced the growing interest in innovative solutions for complex IOL fixation cases.
As the GOLDEN GATE trial moves forward, it will play a crucial role in determining whether LensOne can fulfill its promise as a transformative device in ophthalmic surgery. If successful, the study could pave the way for regulatory approval and broader clinical adoption, ultimately offering a standardized and effective solution for a patient population that currently faces limited options.
In the broader context of ophthalmic innovation, the advancement of LensOne reflects a continued push toward improving surgical precision, patient safety, and long-term outcomes. By addressing a well-recognized gap in current treatment approaches, Long Bridge Medical is positioning itself at the forefront of efforts to redefine care for patients requiring secondary intraocular lens implantation.
About LensOne
LensOne is an investigational, prosthetic capsular bag designed to restore the anatomic foundation needed for standard IOL implantation in eyes lacking capsule support who are poor candidates for ACIOL. Designed to support a variety of IOL types, LensOne enables surgeons to use familiar techniques in complex cases previously requiring high-risk surgical alternatives. CAUTION—Investigational device. Limited by United States law to investigational use.
About Long Bridge Medical
Long Bridge Medical is a South San Francisco-based ophthalmic device company developing solutions for complex IOL fixation. The company is backed by leading ophthalmic surgeons and life science investors committed to advancing vision care.
Source Link:https://www.businesswire.com/
